The 43rd annual J.P. Morgan Healthcare Conference begins in San Francisco under tighter security and market uncertainty, but …
The 43rd annual J.P. Morgan Healthcare Conference begins in San Francisco under tighter security and market uncertainty, but …
Hoyos’s inhaled mRNA-based therapy enters first-in-human testing for asthma—a milestone that could redefine treatment for chronic respiratory disease.
Stablepharma moves toward first-in-human testing of SPVX02, a thermally stable tetanus–diphtheria booster that could revolutionise vaccine storage and …
A three-year collaboration between Vertex and Orna Therapeutics brings cutting-edge lipid nanoparticle delivery into the spotlight, aiming to …
With a PDUFA date set for June 2025, the copper histidinate therapy may soon become the first FDA-approved …
A novel collaboration breaks ground with an inhaled mRNA therapy entering early clinical testing for the first time—a …
Generative AI has produced a novel TNIK-inhibiting compound now advancing in phase 2a trials—an unprecedented milestone in drug discovery.
A landmark U.S. FDA nod for Datopotamab deruxtecan (Datroway) marks a promising advance for treating metastatic HR‑positive, HER2‑negative …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
A pivotal agreement between uniQure and the FDA ignites momentum for Huntington’s gene therapy, while Europe’s regulatory landscape …
